1. Scrip
  2. >>Business
  3. >>Start-Ups & SMEs

Synthetic Biologics CEO On Pipeline Advances And The Microbiome

 
• By Lucie Ellis-Taitt

Scrip senior editor Lucie Ellis speaks to Jeff Riley, president and CEO of Synthetic Biologics, on the sidelines of the recent BIO-Europe partnering conference in Berlin about how the company is harnessing the microbiome to develop two late-stage therapeutics.

Video interview

Synthetic Biologics Inc.'s CEO Jeff Riley talks about why the biopharma industry is interested now in the greater use of microbiome-focused techniques within drug R&D. He also highlights challenges within this research space and what to look out for from Synthetic Biologics in 2018.

Synthetic Biologics, a clinical company based in the US, has two drug candidates in development – ribaxamase and SYN-010 –...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Start-Ups & SMEs

Spain’s SpliceBio Secures Sanofi and Roche Support In $135m Financing

 
• By Kevin Grogan

Series B cash will be used to advance its Stargardt disease gene therapy.

All Over For iTeos But Applause For Plan To Return Cash Fast

 
• By Kevin Grogan

The company has moved quickly to wind down operations after its anti-TIGIT pact with GSK collapsed.

Sweden’s Hansa Slims Down Ahead of Key Readouts

 
• By Kevin Grogan

New CEO Renée Aguiar-Lucander is marking her mark.

End Is Nigh For 4SC After EMA’s No For Kinselby

 
• By Kevin Grogan

The German biotech has discontinued the oral HDAC inhibitor for cutaneous T-cell lymphoma.

More from Business

BioNTech To Buy mRNA Rivals CureVac

 
• By Andrew McConaghie

The $1.25bn buyout is a simple deal for BioNTech, bringing new mRNA R&D and manufacturing capacity while also ending a bothersome patent dispute.

Is Zydus’s Agenus Deal Opportunistic Or Strategic?

 
• By Vibha Ravi

Will Zydus’s acquisition and licensing deal with Agenus turn out to be a strategic move towards building an oncology portfolio or an opportunistic one driven by a venture capital mindset?

Biogen Lays Out Cadence For Felzartamab Data In Kidney Diseases

 
• By Jessica Merrill

The first Phase III data for the CD38-targeting antibody is expected in 2027 in antibody-mediated rejection in kidney transplant patients, followed by other indications.